Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells

Bcr-Abl tyrosine kinase inhibitor STI-571 induces differentiation and apoptosis of HL-60/Bcr-Abl (with ectopic expression of p190 Bcr-Abl) and K562 (with endogenous expression of p210 Bcr-Abl) cells (Blood, 96: 2246–2253, 2000). Cotreatment with STI-571 partially overcomes the resistance to antileuk...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2001-02, Vol.7 (2), p.350-357
Hauptverfasser:	NIMMANAPALLI, Ramadevi, POROSNICU, Mercedes, NGUYEN, Diep, WORTHINGTON, Elizabeth, O'BRYAN, Erica, PERKINS, Charles, BHALLA, Kapil
Format:	Artikel
Sprache:	eng
Schlagworte:	Annexin A5 - metabolism Antineoplastic agents Antineoplastic Agents - pharmacology Apoptosis - drug effects Apoptosis Regulatory Proteins Benzamides Biological and medical sciences Blotting, Western Chemotherapy Cytochrome c Group - metabolism Drug Combinations Drug Synergism Genes, abl - genetics Humans Imatinib Mesylate Leukemia - drug therapy Leukemia - genetics Leukemia - metabolism Ligands Medical sciences Membrane Glycoproteins - pharmacology Pharmacology. Drug treatments Piperazines - pharmacology Pyrimidines - pharmacology TNF-Related Apoptosis-Inducing Ligand Tumor Cells, Cultured - drug effects Tumor Cells, Cultured - metabolism Tumor Necrosis Factor-alpha - metabolism Tumor Necrosis Factor-alpha - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!